HLA-DR Genotyping
Also known as: HLA-DR DNA
Use
HLA-DR Genotyping is used for immunization/vaccination trials or to aid in the clinical diagnosis of diseases strongly associated with the HLA-DR locus. The test provides information critical for patients involved in treatment protocols requiring specific HLA-DR allele identifications. It assists healthcare providers in making informed clinical decisions for diagnosis or trial suitability based on HLA-DR genetic information.
Special Instructions
Not provided.
Limitations
The presence of a disease-associated HLA combination does not establish a diagnosis. If less than 2 alleles are reported for a locus, the patient is likely homozygous. Rare diagnostic errors can occur due to primer or probe site mutations. This test is not sufficient for comprehensive HLA evaluation for clinical hematopoietic stem cell transplantation. For pre-transplant allele matching, consider HLA Class I and II Panel by Next Generation Sequencing. Occasionally, the specific allele cannot be determined, and the most likely allele assignment is made, indicating other possible allele assignments.
New York Approved
Methodology
PCR-based (Sequence-Specific Oligonucleotide Probe Hybridization)
Biomarkers
HLA-DRB1 Allele 1
AnalyteHLA-DRB1 Allele 2
Analyte
LOINC Codes
- 43290-6 - HLA-DRB1 Ql
- 57298-2 - HLA-DRB1
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL
Minimum Volume
3 mL
Container
Lavender (EDTA), Pink (K2EDTA), or Yellow (ACD Solution A or B) tube
Storage Instructions
Refrigerated
Causes for Rejection
Specimens collected in green (sodium or lithium heparin) tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 1 week |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant